
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Dr Seán McMahon explains how Ashland’s Viatel™ bioresorbable work and rationalizes why formulators should consider using in the development of long acting injectables and implants.
Ashland has launched Viatel™ ultrapure bioresorbable polymers (lactide / glycolide / caprolactone chemistries), a higher purity platform of controlled release polymers used in long acting injectables and implants (LAII). Ultrapure provides improved release consistency, extended-release durations and are better suited for sensitive drug compounds due to the less acidic micro-environment.






